نتائج البحث - "Matthew W. Dudley"

1

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

المساهمون: Targeted Gynaecologic Oncology (TARGON), Centre Eugène Marquis (CRLCC), Tel Aviv University [Tel Aviv], University Medical Center Groningen [Groningen] (UMCG), Victor Babeş University of Medicine and Pharmacy (UMFT), Masaryk Memorial Cancer Institute (RECAMO), Universidad de la frontera [Chile], The University of Texas M.D. Anderson Cancer Center [Houston]

المصدر: Lancet Oncology, 21(10), 1269-1282. ELSEVIER SCIENCE INC
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21, pp.1269-1282. ⟨10.1016/S1470-2045(20)30447-2⟩
Diéras, V, Han, H S, Kaufman, B, Wildiers, H, Friedlander, M, Ayoub, J P, Puhalla, S L, Bondarenko, I, Campone, M, Jakobsen, E H, Jalving, M, Oprean, C, Palácová, M, Park, Y H, Shparyk, Y, Yañez, E, Khandelwal, N, Kundu, M G, Dudley, M, Ratajczak, C K, Maag, D & Arun, B K 2020, ' Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet Oncology, vol. 21, no. 10, pp. 1269-1282 . https://doi.org/10.1016/S1470-2045(20)30447-2

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, Veliparib, Drug-Related Side Effects and Adverse Reactions, Organoplatinum Compounds, Paclitaxel, [SDV]Life Sciences [q-bio], Population, Genes, BRCA2, Genes, BRCA1, Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Placebo, Drug Administration Schedule, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, education, Germ-Line Mutation, education.field_of_study, business.industry, BRCA mutation, Middle Aged, medicine.disease, Progression-Free Survival, 3. Good health, 030104 developmental biology, Treatment Outcome, chemistry, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Benzimidazoles, Female, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b18c4df7a7a8a391ea38d376c5a98ec
https://research.rug.nl/en/publications/6f200398-3890-4954-95e6-fe24d6b953a3

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

2

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

المساهمون: Targeted Gynaecologic Oncology (TARGON)

المصدر: Annals of Oncology, 30, 857-858. Oxford University Press
Dieras, V C, Han, H S, Kaufman, B, Wildiers, H, Friedlander, M, Ayoub, J-P, Puhalla, S L, Bondarenko, I, Campone, M, Jakobsen, E H, Jalving, M, Oprean, C, Palacova, M, Park, Y H, Shparyk, Y, Yanez, E, Dudley, M, Ratajczak, C K, Maag, D & Arun, B K 2019, ' Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ', Annals of Oncology, vol. 30, no. Suppl. 5, LBA9, pp. 857-858 . https://doi.org/10.1093/annonc/mdz394.008

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Veliparib, Surrogate endpoint, business.industry, Hematology, Neutropenia, medicine.disease, Chemotherapy regimen, Carboplatin, chemistry.chemical_compound, Breast cancer, chemistry, Paclitaxel, Internal medicine, medicine, Progression-free survival, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c5a8373a32ca232d0d8bead43e7919
https://research.rug.nl/en/publications/acdc7db2-ed8e-45e8-9245-4d37956c9c3a

3

Managing Multiple Myeloma in Older Adults Using Real World Evidence and Clinical Integration of a Geriatric Assessment Tool in Clinical Practice

المؤلفون: Julie M Scott, D'Ambra Dent, Matthew W. Dudley, Gayathri Ravi, Debra Wujcik, Kelly N. Godby, William N. Dudley, Smith Giri, Stacey A. Ingram, Luciano J. Costa, Susan Bal

المصدر: Blood. 138:5019-5019

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, Geriatric assessment, Cell Biology, Hematology, medicine.disease, Real world evidence, Biochemistry, Clinical Practice, Medicine, business, Intensive care medicine, Multiple myeloma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::1691852d538c0d81af6611a65cf19144
https://doi.org/10.1182/blood-2021-153753

4

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Acute Myelogenous Leukemia to Drive Personalized Treatment Decisions

المؤلفون: Stacey A. Ingram, Debra Wujcik, Omer Jamy, Julie M Scott, Matthew W. Dudley, William N. Dudley, D'Ambra Dent

المصدر: Blood. 138:4050-4050

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, Personalized treatment, Geriatric assessment, Cell Biology, Hematology, medicine.disease, Biochemistry, law.invention, Myelogenous, Leukemia, Touchscreen, law, medicine, Intensive care medicine, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d746edfb00b5a62853908b5539381df9
https://doi.org/10.1182/blood-2021-148806

5

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study

المؤلفون: Philip Komarnitsky, Matthew W. Dudley, Dustin A. Deming, Samuel Y Ngan, Brian G. Czito, Lei He, Mary F. Mulcahy, Wijith Munasinghe, Angela DeLuca, John Zalcberg, Kyle D. Holen, Rajendar K. Mittapalli, Michael Michael, Houman Vaghefi, Gayle S. Jameson

المصدر: The Lancet Gastroenterology & Hepatology. 2:418-426

مصطلحات موضوعية: Adult, Diarrhea, Male, 0301 basic medicine, medicine.medical_specialty, Maximum Tolerated Dose, Veliparib, medicine.medical_treatment, Antineoplastic Agents, Adenocarcinoma, Poly(ADP-ribose) Polymerase Inhibitors, Capecitabine, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, Humans, Fatigue, Neoadjuvant therapy, Aged, Neoplasm Staging, Hepatology, Rectal Neoplasms, business.industry, Gastroenterology, Nausea, Chemoradiotherapy, Middle Aged, Total mesorectal excision, Neoadjuvant Therapy, Oxaliplatin, Surgery, Radiation therapy, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Benzimidazoles, Female, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0c3298d5aff4be85deed3990e6975d
https://doi.org/10.1016/s2468-1253(17)30012-2

6

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

المساهمون: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology

المصدر: Gynecologic Oncology, 153, 127-134
Gynecologic Oncology, 153(1), 127-134. ACADEMIC PRESS INC ELSEVIER SCIENCE
Gynecologic Oncology, 153, 1, pp. 127-134
Gynecologic Oncology, 153(1), 127-134. Academic Press

مصطلحات موضوعية: 0301 basic medicine, DNA Repair, Genes, BRCA2, Genes, BRCA1, Poly (ADP-Ribose) Polymerase-1, RAD51, MULTICENTER, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, PARP1, Medicine, Homologous Recombination, PARP inhibitors, Ovarian Neoplasms, Sulfonamides, Obstetrics and Gynecology, HR-deficiency, OPEN-LABEL, 53BP1, POLYMERASE INHIBITORS, Oncology, NIRAPARIB, 030220 oncology & carcinogenesis, Benzamides, PARP inhibitor, Female, Tumor Suppressor p53-Binding Protein 1, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], CARCINOMA, DNA repair, Poly(ADP-ribose) Polymerase Inhibitors, Article, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Ovarian cancer, Cell Line, Tumor, Carcinoma, Humans, Clonogenic assay, REPAIR, business.industry, MUTATIONS, DNA Repair Pathway, medicine.disease, PROFICIENT, 030104 developmental biology, Drug Resistance, Neoplasm, CELLS, Cancer research, DNA damage, business, RESISTANCE